Lisa A. Maier
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Lisa A. Maier has a total of 244 co-authors. Here are the top co-authors by number of shared publications:
Lee S. Newman
5 shared publicationsRichard T. Sawyer
Asthma, Allergy and Inflammation Branch, Division of Allergy, Immunology and Transplantation, National Institute of Allergy and Infectious Disease, National Institutes of Health, Bethesda, USA
3 shared publicationsCecile S. Rose
2 shared publicationsH. Sato
Clinical Genomics Group, Imperial College of Science, Technology and Medicine, London, UK
2 shared publicationsL. S. Newman
Department of Preventive Medicine, University of CO at Denver and Health Sciences Center, Denver, CO, USA
2 shared publicationsLori A. Kittle
2 shared publications
Latest Publications
- 28 October 2010
- Published by Springer Nature in BioMetals
- Vol. 24 (1) , 1-17
Chronic beryllium disease: an updated model interaction between innate and acquired immunity
During the last decade, there have been concerted efforts to reduce beryllium (Be) exposure in the workplace and thereby reduce potential cases of this occupational lung disorder. Despite these efforts, it is estimated that there are at least one million Be-exposed individuals in the U.S. who are potentially at risk for developing chronic beryllium disease (CBD). Previously, we reviewed the current CBD literature and proposed that CBD represents a model interaction between innate and acquired immunity (Sawyer et al., Int Immunopharmacol 2:249–261, 2002). We closed this review with a section on “future directions” that identified key gaps in our understanding of the pathogenesis of CBD. In the intervening period, progress has been made to fill in some of these gaps, and the current review will provide an update on that progress. Based on recent findings, we provide a new hypothesis to explain how Be drives sustained chronic inflammation and granuloma formation in CBD leading to progressive compromised lung function in CBD patients. This paradigm has direct implications for our understanding of the development of an immune response to Be, but is also likely applicable to other immune-mediated lung diseases of known and unknown etiology.
- 28 October 2010
- Published by Springer Nature in BioMetals
- Vol. 24 (1) , 1-17
Chronic beryllium disease: an updated model interaction between innate and acquired immunity
During the last decade, there have been concerted efforts to reduce beryllium (Be) exposure in the workplace and thereby reduce potential cases of this occupational lung disorder. Despite these efforts, it is estimated that there are at least one million Be-exposed individuals in the U.S. who are potentially at risk for developing chronic beryllium disease (CBD). Previously, we reviewed the current CBD literature and proposed that CBD represents a model interaction between innate and acquired immunity (Sawyer et al., Int Immunopharmacol 2:249–261, 2002). We closed this review with a section on “future directions” that identified key gaps in our understanding of the pathogenesis of CBD. In the intervening period, progress has been made to fill in some of these gaps, and the current review will provide an update on that progress. Based on recent findings, we provide a new hypothesis to explain how Be drives sustained chronic inflammation and granuloma formation in CBD leading to progressive compromised lung function in CBD patients. This paradigm has direct implications for our understanding of the development of an immune response to Be, but is also likely applicable to other immune-mediated lung diseases of known and unknown etiology.
- 1 January 2010
- Published by Elsevier
Contributors
- 28 June 2008
- Published by Wiley in Tissue Antigens
- Vol. 72 (1) , 39-48
Fas promoter polymorphisms: genetic predisposition to sarcoidosis in African‐Americans
Apoptosis may perpetuate some forms of inflammation. Of the apoptotic pathway proteins, Fas is particularly overexpressed in sarcoidosis. We hypothesized that Fas promoter single nucleotide polymorphisms (SNPs) contribute to the development and severity of sarcoidosis. Associations of known Fas promoter SNPs (−670, −690 and −1377) and deduced haplotypes with sarcoidosis and sarcoidosis severity were evaluated using matched case–control (n = 656 pairs) and case–comparison (n = 656) studies, respectively, using conditional logistic regression. Hardy–Weinberg equilibrium was confirmed for all three polymorphisms in African‐Americans (AA), and for the −670 and −1377 in whites. Genotype and allele frequencies were significantly different between whites and AA. Race‐stratified analysis revealed that a common haplotype, −1377G/−690T/−670G, was associated with sarcoidosis [odds ratio (OR) = 1.78, P = 0.05] only in AA. The haplotype −1377G/−690C/−670A was negatively associated with sarcoidosis (OR = 0.39, P = 0.03) only in AA. In conclusion, the consistency of these findings suggests that Fas promoter genetic variants may be related to sarcoidosis disease risk in AA.
- 28 June 2008
- Published by Wiley in Tissue Antigens
- Vol. 72 (1) , 39-48
Fas promoter polymorphisms: genetic predisposition to sarcoidosis in African‐Americans
Apoptosis may perpetuate some forms of inflammation. Of the apoptotic pathway proteins, Fas is particularly overexpressed in sarcoidosis. We hypothesized that Fas promoter single nucleotide polymorphisms (SNPs) contribute to the development and severity of sarcoidosis. Associations of known Fas promoter SNPs (−670, −690 and −1377) and deduced haplotypes with sarcoidosis and sarcoidosis severity were evaluated using matched case–control (n = 656 pairs) and case–comparison (n = 656) studies, respectively, using conditional logistic regression. Hardy–Weinberg equilibrium was confirmed for all three polymorphisms in African‐Americans (AA), and for the −670 and −1377 in whites. Genotype and allele frequencies were significantly different between whites and AA. Race‐stratified analysis revealed that a common haplotype, −1377G/−690T/−670G, was associated with sarcoidosis [odds ratio (OR) = 1.78, P = 0.05] only in AA. The haplotype −1377G/−690C/−670A was negatively associated with sarcoidosis (OR = 0.39, P = 0.03) only in AA. In conclusion, the consistency of these findings suggests that Fas promoter genetic variants may be related to sarcoidosis disease risk in AA.
- 1 May 2008
- Published by Oxford University Press (OUP) in American Journal of Respiratory and Critical Care Medicine
- Vol. 177 (9) , 1012-1017
Recent Chronic Beryllium Disease in Residents Surrounding a Beryllium Facility
Rationale: Between 1948 and 1969, cases of community-acquired chronic beryllium disease (CA-CBD) were reported in neighborhoods surrounding beryllium facilities. Further surveillance was not performed in these communities, and additional cases have not been reported. Objectives: To increase awareness of recently diagnosed cases of CA-CBD in residents surrounding a beryllium facility. Methods: Medical records were reviewed from individuals in a community surrounding a beryllium manufacturing facility in Reading, Pennsylvania. Definite cases of CBD required (1) an abnormal beryllium lymphocyte proliferation test in blood or bronchoalveolar lavage and (2) biopsy evidence of granulomatous inflammation. Probable cases of CBD either displayed an abnormal blood test to beryllium and radiographic evidence consistent with disease, or met epidemiologic criteria for CBD based on the Beryllium Case Registry criteria. Cases with occupational or potential paraoccupational exposure were excluded. Measurements and Main Results: Sixteen cases of potential community-acquired CBD were evaluated. From these, eight cases of community-acquired CBD were identified (five definite and three probable). The cases' initial year of residence began between 1943 and 1953 and continued until 1956–2001. Six of the eight cases required medical treatment and three of the cases died since diagnosis. Conclusions: Cases of CBD meeting current immunologic diagnostic criteria and attributable to industry-associated environmental exposure were detected among residents of a community surrounding a beryllium manufacturing facility. Most were diagnosed years after exposure cessation. The frequency and extent of beryllium disease in this community are unknown. We anticipate that not only have cases been misdiagnosed in this community but that more cases of CBD will be diagnosed in the future.
- 1 May 2008
- Published by Oxford University Press (OUP) in American Journal of Respiratory and Critical Care Medicine
- Vol. 177 (9) , 1012-1017
Recent Chronic Beryllium Disease in Residents Surrounding a Beryllium Facility
Rationale: Between 1948 and 1969, cases of community-acquired chronic beryllium disease (CA-CBD) were reported in neighborhoods surrounding beryllium facilities. Further surveillance was not performed in these communities, and additional cases have not been reported. Objectives: To increase awareness of recently diagnosed cases of CA-CBD in residents surrounding a beryllium facility. Methods: Medical records were reviewed from individuals in a community surrounding a beryllium manufacturing facility in Reading, Pennsylvania. Definite cases of CBD required (1) an abnormal beryllium lymphocyte proliferation test in blood or bronchoalveolar lavage and (2) biopsy evidence of granulomatous inflammation. Probable cases of CBD either displayed an abnormal blood test to beryllium and radiographic evidence consistent with disease, or met epidemiologic criteria for CBD based on the Beryllium Case Registry criteria. Cases with occupational or potential paraoccupational exposure were excluded. Measurements and Main Results: Sixteen cases of potential community-acquired CBD were evaluated. From these, eight cases of community-acquired CBD were identified (five definite and three probable). The cases' initial year of residence began between 1943 and 1953 and continued until 1956–2001. Six of the eight cases required medical treatment and three of the cases died since diagnosis. Conclusions: Cases of CBD meeting current immunologic diagnostic criteria and attributable to industry-associated environmental exposure were detected among residents of a community surrounding a beryllium manufacturing facility. Most were diagnosed years after exposure cessation. The frequency and extent of beryllium disease in this community are unknown. We anticipate that not only have cases been misdiagnosed in this community but that more cases of CBD will be diagnosed in the future.
- 9 October 2007
- Published by Wiley in Tissue Antigens
- Vol. 70 (6) , 480-486
BTNL2 allele associations with chronic beryllium disease in HLA‐DPB1*Glu69–negative individuals
Butyrophilin‐like 2 (BTNL2) polymorphisms have been associated with sarcoidosis. We hypothesized that BTNL2 variants might confer a human leukocyte antigen (HLA)‐independent risk for chronic beryllium disease (CBD), a granulomatous lung disease with similar clinical, radiological, and pathological features to sarcoidosis. Genomic DNA was obtained from CBD (n= 88), beryllium sensitized (BeS, n= 86), and beryllium exposed nondiseased control subjects (Be‐exp, n= 173). Six BTNL2 polymorphisms, HLA‐DPB1, DRB1, and DQB1 alleles were determined by sequence‐specific primer‐PCR. All BTNL2 polymorphisms were in Hardy–Weinberg equilibrium. No significant differences were found between BTNL2 polymorphisms or haplotypes and CBD, BeS, or Be‐exp. In HLA‐DPB1*Glu69–negative subjects (n= 10 CBD, n= 13 BeS, n= 102 Be‐exp), DRB1*13 and BTNL2 rs3117099TT homozygosity were increased in CBD (70% and 40%, respectively) vs Be‐exp (16%, P= 0.001 and 2.9%, P= 0.001, respectively). The BTNL2 rs3117099T–HLA‐DRB1*13 combination was significantly increased in CBD (50%) compared with Be‐exp (6.9%, P= 0.001). In conclusion, both DRB1*13 and rs3117099TT homozygosity are associated with CBD in *Glu69‐negative subjects, while DPB1*Glu69 is associated with CBD and BeS compared with Be‐exp. As a result of the small sample size and strong linkage disequilibrium between DRB1*13‐DQB1*0603/4/9 and the BTNL2 rs3117099T allele, it is difficult to assess the primary association in DPB1*Glu69‐negative CBD cases.
- 9 October 2007
- Published by Wiley in Tissue Antigens
- Vol. 70 (6) , 480-486
BTNL2 allele associations with chronic beryllium disease in HLA‐DPB1*Glu69–negative individuals
Butyrophilin‐like 2 (BTNL2) polymorphisms have been associated with sarcoidosis. We hypothesized that BTNL2 variants might confer a human leukocyte antigen (HLA)‐independent risk for chronic beryllium disease (CBD), a granulomatous lung disease with similar clinical, radiological, and pathological features to sarcoidosis. Genomic DNA was obtained from CBD (n= 88), beryllium sensitized (BeS, n= 86), and beryllium exposed nondiseased control subjects (Be‐exp, n= 173). Six BTNL2 polymorphisms, HLA‐DPB1, DRB1, and DQB1 alleles were determined by sequence‐specific primer‐PCR. All BTNL2 polymorphisms were in Hardy–Weinberg equilibrium. No significant differences were found between BTNL2 polymorphisms or haplotypes and CBD, BeS, or Be‐exp. In HLA‐DPB1*Glu69–negative subjects (n= 10 CBD, n= 13 BeS, n= 102 Be‐exp), DRB1*13 and BTNL2 rs3117099TT homozygosity were increased in CBD (70% and 40%, respectively) vs Be‐exp (16%, P= 0.001 and 2.9%, P= 0.001, respectively). The BTNL2 rs3117099T–HLA‐DRB1*13 combination was significantly increased in CBD (50%) compared with Be‐exp (6.9%, P= 0.001). In conclusion, both DRB1*13 and rs3117099TT homozygosity are associated with CBD in *Glu69‐negative subjects, while DPB1*Glu69 is associated with CBD and BeS compared with Be‐exp. As a result of the small sample size and strong linkage disequilibrium between DRB1*13‐DQB1*0603/4/9 and the BTNL2 rs3117099T allele, it is difficult to assess the primary association in DPB1*Glu69‐negative CBD cases.
- Open Access
- 15 December 2003
- Published by Oxford University Press (OUP) in The Journal of Immunology
- Vol. 171 (12) , 6910-6918
Influence of MHC CLASS II in Susceptibility to Beryllium Sensitization and Chronic Beryllium Disease
A glutamic acid at residue 69(Glu69) in the HLA-DPB1 gene (Glu69) is associated with chronic beryllium disease (CBD) and possibly beryllium sensitization (BeS). This study tested the hypothesis that MHC class II polymorphisms are important in susceptibility to BeS and CBD and that the Glu69 variant is related to markers of disease severity. Genomic DNA was obtained from BeS (n = 50), CBD (n = 104), and beryllium-exposed nondiseased (Be-nondiseased) (n = 125) subjects. HLA-DPB1, -DRB1, and -DQB1 genotypes were determined by (sequence-specific primers) PCR. Disease severity was assessed by pulmonary function and exercise testing. A higher frequency of the DPB1 Glu69 gene was found in CBD and BeS compared with the Be-nondiseased subjects, with odds ratios of 10.1 for CBD vs Be-nondiseased and 9.5 for BeS vs Be-nondiseased. The majority of BeS and CBD subjects displayed non-0201 Glu69 alleles. Glu69 homozygosity was higher in the CBD subjects, while BeS subjects were intermediate and Be-nondiseased lowest. DRB1*01 and DQB1*05 phenotypes were reduced in CBD vs Be-nondiseased subjects, while DRB1*13 and DQB1*06 were associated with CBD in the absence of Glu69. Markers of disease severity, including a lower forced vital capacity, diffusion capacity for carbon monoxide, PaO2 at rest, maximum workload on exercise testing, and a higher arterial-alveolar gradient at rest, were associated with Glu69 homozygosity. We conclude that DPB1 Glu69 is a marker of sensitization and not specific for disease. Glu69 homozygosity acts as a functional marker associated with markers of CBD severity.
- 15 December 2003
- Published by Oxford University Press (OUP) in The Journal of Immunology
- Vol. 171 (12) , 6910-6918
Open AccessInfluence of MHC CLASS II in Susceptibility to Beryllium Sensitization and Chronic Beryllium Disease
A glutamic acid at residue 69(Glu69) in the HLA-DPB1 gene (Glu69) is associated with chronic beryllium disease (CBD) and possibly beryllium sensitization (BeS). This study tested the hypothesis that MHC class II polymorphisms are important in susceptibility to BeS and CBD and that the Glu69 variant is related to markers of disease severity. Genomic DNA was obtained from BeS (n = 50), CBD (n = 104), and beryllium-exposed nondiseased (Be-nondiseased) (n = 125) subjects. HLA-DPB1, -DRB1, and -DQB1 genotypes were determined by (sequence-specific primers) PCR. Disease severity was assessed by pulmonary function and exercise testing. A higher frequency of the DPB1 Glu69 gene was found in CBD and BeS compared with the Be-nondiseased subjects, with odds ratios of 10.1 for CBD vs Be-nondiseased and 9.5 for BeS vs Be-nondiseased. The majority of BeS and CBD subjects displayed non-0201 Glu69 alleles. Glu69 homozygosity was higher in the CBD subjects, while BeS subjects were intermediate and Be-nondiseased lowest. DRB1*01 and DQB1*05 phenotypes were reduced in CBD vs Be-nondiseased subjects, while DRB1*13 and DQB1*06 were associated with CBD in the absence of Glu69. Markers of disease severity, including a lower forced vital capacity, diffusion capacity for carbon monoxide, PaO2 at rest, maximum workload on exercise testing, and a higher arterial-alveolar gradient at rest, were associated with Glu69 homozygosity. We conclude that DPB1 Glu69 is a marker of sensitization and not specific for disease. Glu69 homozygosity acts as a functional marker associated with markers of CBD severity.
- 21 May 2003
- Published by Wiley in American Journal of Industrial Medicine
- Vol. 43 (6) , 592-601
Beryllium‐stimulated neopterin as a diagnostic adjunct in chronic beryllium disease
Background: The diagnosis of chronic beryllium disease (CBD) relies on the beryllium lymphocyte proliferation test (BeLPT) to demonstrate a Be specific immune response. This test has improved early diagnosis, but cannot discriminate beryllium sensitization (BeS) from CBD. We previously found high neopterin levels in CBD patients' serum and questioned whether Be‐stimulated neopterin production by peripheral blood cells in vitro might be useful in the diagnosis of CBD.Methods: CBD, BeS, Be exposed workers without disease (Be‐exp) normal controls and sarcoidosis subjects were enrolled. Peripheral blood mononuclear cells (PBMN) were cultured in the presence and absence of beryllium sulfate. Neopterin levels were determined from cell supernatants by enzyme linked immunosorbent assay (ELISA). Clinical evaluation of CBD subjects included chest radiography, pulmonary function testing, exercise testing, and the BeLPT.Results: CBD patients produced higher levels of neopterin in both unstimulated and Be‐stimulated conditions compared to all other subjects (P < 0.0001). Unstimulated neopterin mononuclear cell levels overlapped among groups, however, Be‐stimulated neopterin levels in CBD showed little overlap. Using a neopterin concentration of 2.5 ng/ml as a cutoff, Be‐stimulated neopterin had a sensitivity of 80% and specificity of 100% for CBD and was able to differentiate CBD from BeS. Be‐stimulated neopterin was inversely related to measures of pulmonary function, exercise capacity, and gas exchange.Conclusions: Neopterin may be a useful diagnostic adjunct in the non‐invasive assessment of CBD, differentiating CBD from BeS. Further studies will be required to determine how it performs in workplace screening. Am. J. Ind. Med. 43:592–601, 2003.
- 21 May 2003
- Published by Wiley in American Journal of Industrial Medicine
- Vol. 43 (6) , 592-601
Beryllium‐stimulated neopterin as a diagnostic adjunct in chronic beryllium disease
Background: The diagnosis of chronic beryllium disease (CBD) relies on the beryllium lymphocyte proliferation test (BeLPT) to demonstrate a Be specific immune response. This test has improved early diagnosis, but cannot discriminate beryllium sensitization (BeS) from CBD. We previously found high neopterin levels in CBD patients' serum and questioned whether Be‐stimulated neopterin production by peripheral blood cells in vitro might be useful in the diagnosis of CBD.Methods: CBD, BeS, Be exposed workers without disease (Be‐exp) normal controls and sarcoidosis subjects were enrolled. Peripheral blood mononuclear cells (PBMN) were cultured in the presence and absence of beryllium sulfate. Neopterin levels were determined from cell supernatants by enzyme linked immunosorbent assay (ELISA). Clinical evaluation of CBD subjects included chest radiography, pulmonary function testing, exercise testing, and the BeLPT.Results: CBD patients produced higher levels of neopterin in both unstimulated and Be‐stimulated conditions compared to all other subjects (P < 0.0001). Unstimulated neopterin mononuclear cell levels overlapped among groups, however, Be‐stimulated neopterin levels in CBD showed little overlap. Using a neopterin concentration of 2.5 ng/ml as a cutoff, Be‐stimulated neopterin had a sensitivity of 80% and specificity of 100% for CBD and was able to differentiate CBD from BeS. Be‐stimulated neopterin was inversely related to measures of pulmonary function, exercise capacity, and gas exchange.Conclusions: Neopterin may be a useful diagnostic adjunct in the non‐invasive assessment of CBD, differentiating CBD from BeS. Further studies will be required to determine how it performs in workplace screening. Am. J. Ind. Med. 43:592–601, 2003.
- 1 December 2002
- Published by Elsevier in Clinics in Chest Medicine
- Vol. 23 (4) , 827-839
Genetic and exposure risks for chronic beryllium disease
- 1 December 2002
- Published by Elsevier in Clinics in Chest Medicine
- Vol. 23 (4) , 827-839
Genetic and exposure risks for chronic beryllium disease
- 1 October 2002
- Published by Wolters Kluwer Health in Journal of Thoracic Imaging
- Vol. 17 (4) , 273-284
Clinical Approach to Chronic Beryllium Disease and Other Nonpneumoconiotic Interstitial Lung Diseases
Exposures in the workplace result in a diverse set of diseases ranging from the pneumoconiosis to other interstitial lung diseases to acute lung injury. Physician awareness of the potential disease manifestations associated with specific exposures is important in defining these diseases and in preventing additional disease. Most occupational diseases mimic other forms of lung disease, including pulmonary fibrosis, sarcoidosis, adult respiratory distress syndrome (ARDS), and bronchiolitis. A “sarcoidosis”-like syndrome, usually limited to the lungs, may result from exposure to bioaerosols and a number of metals. Exposure to beryllium in the workplace produces a granulomatous lung disease clinically indistinguishable from sarcoidosis, chronic beryllium disease (CBD). Beryllium's ability to produce a beryllium-specific immune response is used in the beryllium lymphocyte proliferation tests to confirm a diagnosis of CBD and exclude sarcoidosis. Exposure to other metals must also be considered in the differential diagnosis of sarcoidosis. When an individual presents acutely with ARDS or acute lung injury, an acute inhalational exposure must be considered. Exposure to a number of irritant substances at high levels may cause a “chemical pneumonitis” or acute lung injury, depending on the solubility and physicochemical properties of the substance. Some of the most notable agents include nitrogen and sulfur oxides, phosgene, and smoke breakdown products. Ingestion of paraquat may also result in an ARDS syndrome, with pulmonary fibrosis eventually resulting. Bronchiolitis is a rare manifestation of inhalational exposures but must also be considered in the clinical evaluation of inhalational exposure.
- 1 October 2002
- Published by Wolters Kluwer Health in Journal of Thoracic Imaging
- Vol. 17 (4) , 273-284
Clinical Approach to Chronic Beryllium Disease and Other Nonpneumoconiotic Interstitial Lung Diseases
Exposures in the workplace result in a diverse set of diseases ranging from the pneumoconiosis to other interstitial lung diseases to acute lung injury. Physician awareness of the potential disease manifestations associated with specific exposures is important in defining these diseases and in preventing additional disease. Most occupational diseases mimic other forms of lung disease, including pulmonary fibrosis, sarcoidosis, adult respiratory distress syndrome (ARDS), and bronchiolitis. A “sarcoidosis”-like syndrome, usually limited to the lungs, may result from exposure to bioaerosols and a number of metals. Exposure to beryllium in the workplace produces a granulomatous lung disease clinically indistinguishable from sarcoidosis, chronic beryllium disease (CBD). Beryllium's ability to produce a beryllium-specific immune response is used in the beryllium lymphocyte proliferation tests to confirm a diagnosis of CBD and exclude sarcoidosis. Exposure to other metals must also be considered in the differential diagnosis of sarcoidosis. When an individual presents acutely with ARDS or acute lung injury, an acute inhalational exposure must be considered. Exposure to a number of irritant substances at high levels may cause a “chemical pneumonitis” or acute lung injury, depending on the solubility and physicochemical properties of the substance. Some of the most notable agents include nitrogen and sulfur oxides, phosgene, and smoke breakdown products. Ingestion of paraquat may also result in an ARDS syndrome, with pulmonary fibrosis eventually resulting. Bronchiolitis is a rare manifestation of inhalational exposures but must also be considered in the clinical evaluation of inhalational exposure.